A breakthrough in the field of medicinal chemistry has emerged from the laboratories at MIT, where chemists have developed an innovative method for synthesizing plant-derived molecules that may offer new avenues for pharmaceutical development. These molecules, termed oligocyclotryptamines, are originally isolated from plants and possess potential applications as antibiotics, painkillers, and cancer treatments. The significant aspect of this development lies in the chemists' ability to accurately assemble complex structures and control their three-dimensional orientation, according to a study published today in the Journal of the American Chemical Society.
The compounds in question are part of the alkaloid family, produced mostly by plants and notable for their inclusion of nitrogen. Oligocyclotryptamines, specifically, are a challenge to synthesize due to their intricate structure featuring multiple cyclotryptamine rings joined by carbon-carbon bonds. Historically, obtaining substantial quantities of these molecules for comprehensive research has been difficult. "For many of these compounds, there hasn't been enough material to do a thorough review of their potential. I’m hopeful that having access to these compounds in a reliable way will enable us to do further studies," MIT professor of chemistry Mohammad Movassaghi told MIT News.
MIT's methodology relies on what is known as diazene-directed assembly, a process that allows for adding necessary components to a molecule sequentially, ensuring precise control over the final product's shape and features. This technique was perfected by Movassaghi's team after years of research into forming strong carbon-carbon bonds in challenging chemical environments. The approach involves inducing carbon radicals to unite selectively under the influence of light, allowing for the stereochemistry of the molecule to be manipulated. Tony Scott, lead author of the study and recent PhD graduate, worked with Movassaghi to apply this technique, yielding oligocyclotryptamines with up to seven interconnected cyclotryptamine rings.
The ability to manufacture these complex molecules synthetically not only provides ample material for research into their potential medical uses but also opens the door to generating novel variants with possible enhanced therapeutic properties. These findings mark a significant stride in the realm of organic synthesis, one that Yale University chemistry professor Seth Herzon calls "a tour de force." He attested to the importance of the work. Herzon's perspective, cited by MIT News, emphasizes the potential impact this discovery could have on future pharmaceutical explorations.
Movassaghi's team has now set their sights on further employing the diazene-directed assembly technique to construct even more complex structures that have yet to be addressed, including derivatives that may possess superior medicinal qualities. The research has been backed by the U.S. National Institute of General Medical Sciences, solidifying the foundation for subsequent investigative endeavors.
